Therefore, this study aimed to assess the level of GDF15 in patients with late-onset MADD and to evaluate its potential as a reliable biomarker for diagnosing symptoms and determining the severity of late-onset MADD. The gene discussed is GDF15; the disease is multiple acyl-CoA dehydrogenase deficiency.